MedinCell S.A. (MEDCL.PA)
EUR 15.48
(1.84%)
EUR 15.48
(1.84%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 9.28 Million EUR | -32.92% |
| 2022 | 13.65 Million EUR | 63.77% |
| 2021 | 8.33 Million EUR | 23.8% |
| 2020 | 6.73 Million EUR | 257.67% |
| 2019 | 1.88 Million EUR | 333.87% |
| 2018 | 434 Thousand EUR | -93.02% |
| 2017 | 6.22 Million EUR | -18.67% |
| 2016 | 7.64 Million EUR | -3.19% |
| 2015 | 7.9 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 FY | 9.16 Million EUR | -32.92% |
| 2023 Q2 | 8.18 Million EUR | 0.0% |
| 2023 Q4 | 3.76 Million EUR | 0.0% |
| 2022 Q2 | 7.7 Million EUR | 0.0% |
| 2022 Q4 | 5.94 Million EUR | 0.0% |
| 2022 FY | 13.65 Million EUR | 63.77% |
| 2021 Q2 | 4.07 Million EUR | 0.0% |
| 2021 Q4 | 4.25 Million EUR | 0.0% |
| 2021 FY | 8.33 Million EUR | 23.8% |
| 2020 FY | 6.73 Million EUR | 257.67% |
| 2020 Q4 | 5.04 Million EUR | 0.0% |
| 2020 Q2 | 3.14 Million EUR | 0.0% |
| 2019 Q4 | 2.09 Million EUR | 0.0% |
| 2019 FY | 1.88 Million EUR | 333.87% |
| 2019 Q2 | 3.9 Million EUR | 0.0% |
| 2018 Q4 | 2.24 Million EUR | 100.0% |
| 2018 Q3 | 1.12 Million EUR | -34.85% |
| 2018 Q1 | 861.5 Thousand EUR | -84.07% |
| 2018 Q2 | 1.72 Million EUR | 100.0% |
| 2018 FY | 434 Thousand EUR | -93.02% |
| 2017 Q2 | 2.67 Million EUR | 100.0% |
| 2017 Q4 | 5.4 Million EUR | 100.0% |
| 2017 FY | 6.22 Million EUR | -18.67% |
| 2017 Q3 | 2.7 Million EUR | 1.08% |
| 2017 Q1 | 1.33 Million EUR | 0.0% |
| 2016 FY | 7.64 Million EUR | -3.19% |
| 2015 FY | 7.9 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -1402.913% |
| ABIVAX Société Anonyme | 3.91 Million EUR | -137.302% |
| Adocia SA | 1.38 Million EUR | -570.614% |
| Aelis Farma SA | 12.35 Million EUR | 24.842% |
| Biophytis S.A. | -803 Thousand EUR | 1256.663% |
| Advicenne S.A. | 1.42 Million EUR | -551.332% |
| genOway Société anonyme | 20.1 Million EUR | 53.792% |
| IntegraGen SA | 5.01 Million EUR | -85.083% |
| Medesis Pharma S.A. | -2.66 Million EUR | 448.548% |
| Neovacs S.A. | 29.31 Thousand EUR | -31584.519% |
| NFL Biosciences SA | -56.06 Thousand EUR | 16666.781% |
| Plant Advanced Technologies SA | 2.15 Million EUR | -331.415% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 754.412% |
| Sensorion SA | 3.78 Million EUR | -145.204% |
| Theranexus Société Anonyme | -4.63 Million EUR | 300.229% |
| TME Pharma N.V. | -127 Thousand EUR | 7413.386% |
| Valbiotis SA | 2.66 Million EUR | -248.126% |
| TheraVet SA | -530.79 Thousand EUR | 1849.825% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -633.07% |
| DBV Technologies S.A. | 4.15 Million EUR | -123.291% |
| Genfit S.A. | 28.22 Million EUR | 67.092% |
| GeNeuro SA | -293.8 Thousand EUR | 3261.334% |
| Innate Pharma S.A. | -4.12 Million EUR | 325.382% |
| Inventiva S.A. | 17.5 Million EUR | 46.926% |
| MaaT Pharma SA | 1.65 Million EUR | -461.208% |
| Nanobiotix S.A. | 36.2 Million EUR | 74.348% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -317.063% |
| Poxel S.A. | 1000.00 EUR | -928700.0% |
| GenSight Biologics S.A. | 3 Million EUR | -209.6% |
| Transgene SA | -28.4 Million EUR | 132.7% |
| Valneva SE | 52.83 Million EUR | 82.421% |